Public Policy Letters, Statements, Legal Briefs, & Other Responses
-
Sign-on Letter to Congressional Leadership Concerning the VALID Act
-
ACMG Comments on FDA Draft Guidance for Products Incorporating Genome Editing
-
Group Sign-on Letter Concerning the VALID Act of 2022 Discussion Draft
-
ACMG Response to Opposing Inclusion of the VALID Act in the FDASLA Act
-
Group Sign-on Letter to CMS Regarding Split or Shared Visits
-
Group Sign-on Letter to Congress Supporting the Reducing Hereditary Cancer Act
-
Group Sign-On Letter Regarding Telehealth Extension Legislation
-
ACMG Response to RFI on NIH Genomic Data Sharing Policy
-
Group Sign-On Letter Concerning the VA Supremacy Project
-
Group Sign-On Letter Urging CLIAC to Discuss CLIA Modernization